Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040492 · ClinicalTrials.gov registry record
Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk
A clinical trial of Skin Cancer, Non-Melanoma, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT03040492: Completed study of Skin Cancer, Non-Melanoma, sponsored by University of Alabama at Birmingham.
NCT03040492 is a study of Skin Cancer, Non-Melanoma that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03040492, a study of Skin Cancer, Non-Melanoma, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as physical characteristics (e.g., ethnicity), family history, and cancer diagnosis will be collected in order to determine if there are relationships between the gene polymorphisms, cancer diagnosis, and these characteristics.
Primary Outcome
Number of patients with the presence or absence of VDR SNP in their DNA isolated from their blood samples. PCR will be performed on the DNA samples for using specific primers for SNP, and the PCR products will be sequenced for detection of SNP.
Conditions Studied
Study Locations (1)
Alabama
- The Kirklin Clinic - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2012-10-31 |
| Est. Completion | 2017-06-30 |
What the finished NCT03040492 record still lists
NCT03040492 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Skin Cancer, Non-Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT03040492 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03040492 about?
NCT03040492 is a clinical study titled "Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk". The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as phys...
What is the current status of trial NCT03040492?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2012-10-31. Estimated completion is 2017-06-30.
What conditions does trial NCT03040492 study?
This clinical trial studies the following conditions: Skin Cancer, Non-Melanoma.
Who is sponsoring clinical trial NCT03040492?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03040492 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer, Non-Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI